Find in Library

<p><strong>Background: </strong>Prostate cancer is the most common cancer in men. Prostate specifi c antigen is a key tumor marker to screen for prostate cancer. However, controversy exits regarding the impact of prostate cancer screening.</p> <p><strong>Materials and Methods: </strong>This was a retrospective study carried out in the Department of Histopathology of B and B Hospital during a period of 2 years from 01-05-2064 to 01-05-2066. The study included 26 cases of prostate needle biopsy specimens.</p> <p><strong>Results: </strong>The more common age group (43.9%) was 70-79 years followed by the age group above 80 years old (7.5%). The most common benign lesion observed was benign prostatic hyperplasia (5 out of 11, 45.45%), followed by benign prostatic hyperplasia with chronic prostatitis (3 out of 11, 27.27%). The most common malignant types of lesion encountered was prostatic adenocarcinoma with an incidence of 84.62% (11 out of 13 cases), following nodular hyperplasia of prostate with low grade prostatic intraepithelial neoplasm 15.38% (2 out of 13 cases). Among the benign and the malignant cases serum PSA ranged from 0 - ?10.1 ng/ml.</p> <p><strong>Conclusion: </strong>Serum PSA value has signifi cant role in the diagnosis of malignant prostatic lesions. However, Histological diagnosis still remains the gold standard for the diagnosis of prostatic cancer.</p> <p>Journal of Pathology of Nepal (2013) Vol. 3, No.1, Issue 5, 394-396</p> <p>DOI: <a href="http://dx.doi.org/10.3126/jpn.v3i5.7865">http://dx.doi.org/10.3126/jpn.v3i5.7865</a></p>